^
    Back
    Association details:
    Biomarker:IDH1 mutation
    Cancer:Astrocytoma
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    ADULT GLIOMA: IDH-MUTANT ASTROCYTOMA….Recurrent Disease, WHO grade 3, KPS ≥60….Preferred Regimens...bevacizumab
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    ADULT GLIOMA: IDH-MUTANT ASTROCYTOMA….Recurrent Disease, WHO grade 3, KPS ≥60….Other Recommended Regimens...Systemic therapy+ bevacizumab...Carmustine or lomustine + bevacizumab...TMZ + bevacizumab
    Secondary therapy:
    lomustine; carmustine; temozolomide
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent Grade III Malignant Astrocytoma

    Excerpt:
    ...Does the treatment significantly modify the patient's quality of life?`Correlations with established molecular markers (ATRX, TERT promoter and/or IDH1 mutation and MGMT promoter methylation...
    Trial ID:
    NCT03450850